Biogen Completes Acquisition of RayThera Inc.
Lead program now in Phase 1 development CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The acquisition strengthens Biogen’s growing immunology portfolio, adding multiple assets that…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
